Cyclopharm Email Formats
Medical Equipment Manufacturing • 
Sydney, New South Wales, Australia • 11-20 Employees
Cyclopharm Email Formats
Cyclopharm uses 2 email formats. The most common is {first name}{last name} (e.g., johndoe@cyclopharm.com.au), used 66.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@cyclopharm.com.au | 66.7% |
{first initial}{last name} | jdoe@cyclopharm.com.au | 33.3% |
Key Contacts at Cyclopharm
James Mcbrayer
Managing Director & Ceo
John Wigglesworth Bec Macq
Non Executive Director, Chairman Audit & Risk Committee
Company overview
| Headquarters | 1 The Crescent, Unit 1, Kingsgrove, NSW 2208, AU |
| Phone number | +61295410411 |
| Websites | |
| SIC | 807 |
| Keywords | Medical Devices, Diagnostic Imaging, Nuclear Medicine, Respiratory Medicine |
| Founded | 1986 |
| Employees | 11-20 |
| Socials |
About Cyclopharm
Cyclopharm is an Australian ASX listed medical device company primarily involved in the field of nuclear medicine. Technegas, Cyclopharm’s foundation product is a lung ventilation imaging agent, is a structured ultra-fine dispersion of radioactive labeled carbon. Technegas is produced by drying Technetium-99m, (the most commonly used isotope in nuclear medicine imaging), in a carbon crucible then heating the isotope for a few seconds at around 2,700oC in a Technegas Generator. The resultant gas-like substance is inhaled by the patient (referred to as lung ventilation) via our consumable product known as a Patient Administration Set (PAS). The inhaled Technegas particles enables multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for superior functional ventilation imaging. Technegas is best known for its use in diagnosing Pulmonary Embolism (PE); however, Technegas is now being investigated for additional indications to include the diagnosis and management of COPD, Asthma, CTEPH and the effectiveness of lung reduction interventions Ultralute, a new product developed by Cyclopharm will be released to the market later in 2016. This first in class, proprietary technology is designed to improve the efficiency, productivity and health care economics in the production of radiopharmaceuticals.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Cyclopharm has 9 employees across 6 departments.
Departments
Number of employees
Funding Data
Cyclopharm has never raised funding before.
United Kingdom
Norway
United States
CanadaFrequently asked questions
4.8
40,000 users
